Silva v. Sayer

District Court, S.D. California·Decided December 16, 2024·No. 3:24-cv-01645·Unknown

Opinion

NATHAN C. SILVA, derivatively on Case No.: 24-cv-1645-RSH-VET behalf of DEXCOM, INC., 24-cv-1799-RSH-VET

Plaintiff, ORDER GRANTING IN PART AND v. DENYING IN PART JOINT MOTION TO CONSOLIDATE, APPOINT KEVIN R. SAYER, et al., LEAD CO-COUNSEL, AND STAY Defendants. PROCEEDINGS

[ECF No. 4]

JEROME MALONE, derivatively on behalf of DEXCOM, INC., Plaintiff, v. KEVIN R. SAYER, et al., Defendants.

Before the Court is a joint motion to consolidate, appoint lead co-counsel, and stay proceedings filed by the Parties in Silva v. Sayer et al., 24cv1645-RSH-VET (“Silva”) and Malone v. Sayer et al., 24cv1799-RSH-VET (“Malone,” collectively “Related Actions”). Pursuant to Local Civil Rule 7.1(d)(1), the Court finds the motion presented appropriate for resolution without oral argument. For the reasons below, the Court grants in part and denies in part the motion. A. Factual Background The instant cases are shareholder derivative actions brought on behalf of nominal defendant Dexcom, Inc. (“Dexcom”) against current and former Dexcom board members and executive officers (“Individual Defendants”).1 Silva, ECF No. 1; Malone, ECF No. 1. Dexcom is a “biotechnology company based in San Diego, California that manufactures and distributes continuous glucose monitoring” systems. Silva, ECF No. 1 ¶ 2. Plaintiffs are Dexcom shareholders. Silva, ECF No. 1 ¶ 6; Malone, ECF No. 1 ¶ 21. Plaintiffs allege that between January 8, 2024 and July 25, 2024, the Individual Defendants disseminated materially false and misleading statements regarding, among other things, the sustainability of Dexcom’s growth, ability to acquire new customers, and sales constraints. Silva, ECF No. 1 ¶ 4; Malone, ECF No. 1 ¶ 3. According to Plaintiffs, the truth was later revealed through a press release announcing disappointing financial results for the second quarter of fiscal year 2024. Silva, ECF No. 1 ¶ 5; Malone, ECF No. 1 ¶ 5. After the press release, the price of Dexcom’s stock declined 40.66% in a single day. Silva, ECF No. 1 ¶ 6; Malone, ECF No. 1 ¶ 6. B. Procedural Background The Silva action was filed on September 13, 2024 and the Malone action was filed shortly thereafter on October 7, 2024. Silva, ECF No. 1; Malone, ECF No. 1. The Court subsequently filed a Notice of Related cases and the two cases were reassigned to the undersigned. Silva, ECF Nos. 3; 5; Malone, ECF Nos. 4; 6. On October 16, 2024, the Parties filed the instant joint motion to consolidate, appoint lead co-counsel for Plaintiffs, and stay proceedings. Silva, ECF No. 4. On November 14, 2024, the Court requested

1 The Individual Defendants named in the derivative suits are Kevin R. Sayer, Jereme M. Sylvain, Steven R. Altman, Nick Augustinos, Richard A. Collins, Karen Dahut, Rimma Driscoll, Mark G. Foletta, Bridgette P. Heller, Kyle Malady, Eric J. Topol, and Barbara E. Kahn. additional briefing from the Parties regarding: (1) the propriety of appointing multiple firms as co-lead counsel in a consolidated shareholder derivative action; and (2) supporting the Parties’ request to stay. ECF No. 6 at 2. On December 13, 2024, the Parties filed a joint brief in response to the Court’s request. ECF No. 9. In addition to these derivative actions, there are three related ongoing securities class actions pending before this Court directed to the same or substantially similar subject matter. Alonzo v. Dexcom Inc., et al., 24cv1485-RSH-VET (“Alonzo”), Oakland County Employees’ Retirement Systems et al. v. Dexcom Inc., et al., 24cv1804-RSH-VET and Carnes v. Dexcom Inc., et al., 24cv1809-RSH-VET (collectively “Federal Securities Class Actions”).2 A. Consolidation The Parties request that the Silva and Malone actions be consolidated. ECF No. 4 ¶ 2. Under Federal Rule of Civil Procedure 42(a), consolidation is appropriate when the actions involve “a common question of law or fact[.]” Fed. R. Civ. P. 42(a). “A district court generally has ‘broad’ discretion to consolidate actions.” Pierce v. Cty. of Orange, 526 F.3d 1190, 1203 (9th Cir. 2008). Here, the Related Actions are brought against the same defendants, allege the same or substantially identical violations of law, and involve the same predicate facts. Both actions are shareholder derivative suits asserted on behalf of nominal defendant Dexcom against Dexcom’s current and former board members and executive officers. Both allege the Individual Defendants made false and misleading statements between January 8, 2024 and July 25, 2024 regarding the sustainability of Dexcom’s growth. Finally, both assert violations of various provisions of federal securities law and related claims, including breach of fiduciary duty. All Parties to the Related Actions have agreed to consolidation.

Free access — add to your briefcase to read the full text and ask questions with AI

Silva v. Sayer, (S.D. Cal. 2024).

Silva v. Sayer (Silva v. Sayer) — published by Counsel Stack Legal Research, free access to 12M+ legal documents.

Related

Landis v. North American Co.
299 U.S. 248 (Supreme Court, 1936)
Pierce v. County of Orange
526 F.3d 1190 (Ninth Circuit, 2008)
MacAlister v. Guterma
263 F.2d 65 (Second Circuit, 1958)
Cmax, Inc. v. Hall
300 F.2d 265 (Ninth Circuit, 1962)